Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation
Identifieur interne : 001D37 ( Main/Exploration ); précédent : 001D36; suivant : 001D38Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation
Auteurs : JUNCHAO TONG [Canada] ; Henry Wong [Canada] ; Mark Guttman [Canada] ; Lee C. Ang [Canada] ; Lysia S. Forno [États-Unis] ; Mitsunobu Shimadzu [Japon] ; Ali H. Rajput [Canada] ; Manfred D. Muenter [États-Unis] ; Stephen J. Kish [Canada] ; Oleh Hornykiewicz [Autriche] ; Yoshiaki Furukawa [Canada, Japon]Source :
- Brain [ 0006-8950 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
α-synuclein is a major component of Lewy bodies and glial cytoplasmic inclusions, pathological hallmarks of idiopathic Parkinson's disease and multiple system atrophy, and it is assumed to be aetiologically involved in these conditions. However, the quantitative status of brain α-synuclein in different Parkinsonian disorders is still unresolved and it is uncertain whether α-synuclein accumulation is restricted to regions of pathology. We compared membrane-associated, sodium dodecyl sulfate-soluble α-synuclein, both the full-length 17 kDa and high molecular weight species, by western blotting in autopsied brain of patients with Parkinson's disease (brainstem-predominant Lewy body disease: n=9), multiple system atrophy (n=11), progressive supranuclear palsy (n = 16), and of normal controls (n = 13). Brain of a patient with familial Parkinsonism-dementia due to α-synuclein locus triplication (as positive control) showed increased membrane-associated, sodium dodecyl sulfate-soluble α-synuclein levels with abundant high molecular weight immunoreactivity. In multiple system atrophy, a massive increase in 17 kDa membrane-associated, sodium dodecyl sulfate-soluble α-synuclein was observed in highly pathologically affected regions, including putamen (+1760%, range +625-2900%), substantia nigra [+1000% (+356-1850%)], and white matter of internal capsule [+2210% (+430-6830%)] together with numerous high molecular weight species. Levels of 17 kDa membrane-associated, sodium dodecyl sulfate-soluble α-synuclein were only modestly increased in less affected areas (cerebellar cortex, +95%; caudate, +30%; with both also showing numerous high molecular weight species) and were generally normal in cerebral cortices. In both Parkinson's disease and progressive supranuclear palsy, membrane-associated, sodium dodecyl sulfate-soluble α-synuclein levels were normal in putamen and frontal cortex whereas a trend was observed for variably increased 17 kDa membrane-associated, sodium dodecyl sulfate-soluble α-synudein concentrations [+184% (-60% to +618%)] with additional high molecular weight species in Parkinson's disease substantia nigra. No obvious correlation was observed between nigral membrane-associated, sodium dodecyl sulfate-soluble (α-synuclein accumulation and Lewy body density in Parkinson's disease. Two progressive supranuclear palsy cases had membrane-associated, sodium dodecyl sulfate-soluble α-synuclein accumulation in substantia nigra similar to multiple system atrophy. Several Parkinson's disease patients had very modest high molecular weight membrane-associated, sodium dodecyl sulfate-soluble α-synuclein accumulation in putamen. Levels of 17-kDa membrane-associated, sodium dodecyl sulfate-soluble α-synuclein were generally positively correlated with those of high molecular weight membrane-associated, sodium dodecyl sulfate-soluble α-synuclein and there was a trend for a positive correlation between striatal dopamine loss and 17-kDa membrane-associated, sodium dodecyl sulfate-soluble α-synuclein concentrations in multiple system atrophy. Brain membrane-associated, sodium dodecyl sulfate-soluble α-synuclein accumulations in Parkinson's disease and multiple system atrophy are regionally specific, suggesting that these sporadic α-synucleinopathies, unlike familial Parkinsonism-dementia, are not associated with a simple global over-expression of the protein. Despite a similar extent of dopamine depletion, the magnitude of brain membrane-associated, sodium dodecyl sulfate-soluble α-synuclein changes is disease specific, with multiple system atrophy clearly having the most severe accumulation. Literature discrepancies on α-synuclein status in 'Parkinson's disease' might be explained by inclusion of cases not having classic brainstem-predominant Lewy body disease and by variable α-synuclein accumulation within this diagnostic classification.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000469
- to stream PascalFrancis, to step Curation: 000808
- to stream PascalFrancis, to step Checkpoint: 000385
- to stream Main, to step Merge: 001E75
- to stream Main, to step Curation: 001D37
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation</title><author><name sortKey="Junchao Tong" sort="Junchao Tong" uniqKey="Junchao Tong" last="Junchao Tong">JUNCHAO TONG</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Wong, Henry" sort="Wong, Henry" uniqKey="Wong H" first="Henry" last="Wong">Henry Wong</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Movement Disorders</s1><s2>Markham, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Centre for Movement Disorders</wicri:noRegion></affiliation></author><author><name sortKey="Ang, Lee C" sort="Ang, Lee C" uniqKey="Ang L" first="Lee C." last="Ang">Lee C. Ang</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology, University of Western Ontario</s1><s2>London, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>London, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Forno, Lysia S" sort="Forno, Lysia S" uniqKey="Forno L" first="Lysia S." last="Forno">Lysia S. Forno</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pathology, VA Palo Alto Health Care System</s1><s2>Palo Alto, CA</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Palo Alto, CA</wicri:noRegion></affiliation></author><author><name sortKey="Shimadzu, Mitsunobu" sort="Shimadzu, Mitsunobu" uniqKey="Shimadzu M" first="Mitsunobu" last="Shimadzu">Mitsunobu Shimadzu</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Mitsubishi Chemical Medience Corporation</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Neurology, University of Saskatchewan</s1><s2>Saskatoon, Saskatchewan</s2><s3>CAN</s3><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Saskatoon, Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="Muenter, Manfred D" sort="Muenter, Manfred D" uniqKey="Muenter M" first="Manfred D." last="Muenter">Manfred D. Muenter</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Neurology, Mayo Clinic Scottsdale</s1><s2>Scottsdale, AZ</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Scottsdale, AZ</wicri:noRegion></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Center for Brain Research, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>10 aut.</sZ></inist:fA14><country>Autriche</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Neurology, Juntendo Tokyo Koto Geriatric Medical Center</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>11 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Neurology, Faculty of Medicine, University & Post Graduate University of Juntendo</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>11 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0060219</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0060219 INIST</idno><idno type="RBID">Pascal:10-0060219</idno><idno type="wicri:Area/PascalFrancis/Corpus">000469</idno><idno type="wicri:Area/PascalFrancis/Curation">000808</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000385</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000385</idno><idno type="wicri:doubleKey">0006-8950:2010:Junchao Tong:brain:synuclein:accumulation</idno><idno type="wicri:Area/Main/Merge">001E75</idno><idno type="wicri:Area/Main/Curation">001D37</idno><idno type="wicri:Area/Main/Exploration">001D37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation</title><author><name sortKey="Junchao Tong" sort="Junchao Tong" uniqKey="Junchao Tong" last="Junchao Tong">JUNCHAO TONG</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Wong, Henry" sort="Wong, Henry" uniqKey="Wong H" first="Henry" last="Wong">Henry Wong</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Centre for Movement Disorders</s1><s2>Markham, Ontario</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Centre for Movement Disorders</wicri:noRegion></affiliation></author><author><name sortKey="Ang, Lee C" sort="Ang, Lee C" uniqKey="Ang L" first="Lee C." last="Ang">Lee C. Ang</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology, University of Western Ontario</s1><s2>London, Ontario</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>London, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Forno, Lysia S" sort="Forno, Lysia S" uniqKey="Forno L" first="Lysia S." last="Forno">Lysia S. Forno</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pathology, VA Palo Alto Health Care System</s1><s2>Palo Alto, CA</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Palo Alto, CA</wicri:noRegion></affiliation></author><author><name sortKey="Shimadzu, Mitsunobu" sort="Shimadzu, Mitsunobu" uniqKey="Shimadzu M" first="Mitsunobu" last="Shimadzu">Mitsunobu Shimadzu</name><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Mitsubishi Chemical Medience Corporation</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>6 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author><author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Division of Neurology, University of Saskatchewan</s1><s2>Saskatoon, Saskatchewan</s2><s3>CAN</s3><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Saskatoon, Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="Muenter, Manfred D" sort="Muenter, Manfred D" uniqKey="Muenter M" first="Manfred D." last="Muenter">Manfred D. Muenter</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Neurology, Mayo Clinic Scottsdale</s1><s2>Scottsdale, AZ</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Scottsdale, AZ</wicri:noRegion></affiliation></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Human Neurochemical Pathology Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Center for Brain Research, University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>10 aut.</sZ></inist:fA14><country>Autriche</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Movement Disorders Research Laboratory, Centre for Addiction and Mental Health</s1><s2>Toronto, Ontario</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>11 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, Ontario</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Department of Neurology, Juntendo Tokyo Koto Geriatric Medical Center</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>11 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Neurology, Faculty of Medicine, University & Post Graduate University of Juntendo</s1><s2>Tokyo</s2><s3>JPN</s3><sZ>11 aut.</sZ></inist:fA14><country>Japon</country><placeName><settlement type="city">Tokyo</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Brain</title><title level="j" type="abbreviated">Brain</title><idno type="ISSN">0006-8950</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Brain</title><title level="j" type="abbreviated">Brain</title><idno type="ISSN">0006-8950</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Encephalon</term><term>Immunoblotting assay</term><term>Multiple system atrophy</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Atrophie multisystématisée</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Encéphale</term><term>Méthode immunoblotting</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">α-synuclein is a major component of Lewy bodies and glial cytoplasmic inclusions, pathological hallmarks of idiopathic Parkinson's disease and multiple system atrophy, and it is assumed to be aetiologically involved in these conditions. However, the quantitative status of brain α-synuclein in different Parkinsonian disorders is still unresolved and it is uncertain whether α-synuclein accumulation is restricted to regions of pathology. We compared membrane-associated, sodium dodecyl sulfate-soluble α-synuclein, both the full-length 17 kDa and high molecular weight species, by western blotting in autopsied brain of patients with Parkinson's disease (brainstem-predominant Lewy body disease: n=9), multiple system atrophy (n=11), progressive supranuclear palsy (n = 16), and of normal controls (n = 13). Brain of a patient with familial Parkinsonism-dementia due to α-synuclein locus triplication (as positive control) showed increased membrane-associated, sodium dodecyl sulfate-soluble α-synuclein levels with abundant high molecular weight immunoreactivity. In multiple system atrophy, a massive increase in 17 kDa membrane-associated, sodium dodecyl sulfate-soluble α-synuclein was observed in highly pathologically affected regions, including putamen (+1760%, range +625-2900%), substantia nigra [+1000% (+356-1850%)], and white matter of internal capsule [+2210% (+430-6830%)] together with numerous high molecular weight species. Levels of 17 kDa membrane-associated, sodium dodecyl sulfate-soluble α-synuclein were only modestly increased in less affected areas (cerebellar cortex, +95%; caudate, +30%; with both also showing numerous high molecular weight species) and were generally normal in cerebral cortices. In both Parkinson's disease and progressive supranuclear palsy, membrane-associated, sodium dodecyl sulfate-soluble α-synuclein levels were normal in putamen and frontal cortex whereas a trend was observed for variably increased 17 kDa membrane-associated, sodium dodecyl sulfate-soluble α-synudein concentrations [+184% (-60% to +618%)] with additional high molecular weight species in Parkinson's disease substantia nigra. No obvious correlation was observed between nigral membrane-associated, sodium dodecyl sulfate-soluble (α-synuclein accumulation and Lewy body density in Parkinson's disease. Two progressive supranuclear palsy cases had membrane-associated, sodium dodecyl sulfate-soluble α-synuclein accumulation in substantia nigra similar to multiple system atrophy. Several Parkinson's disease patients had very modest high molecular weight membrane-associated, sodium dodecyl sulfate-soluble α-synuclein accumulation in putamen. Levels of 17-kDa membrane-associated, sodium dodecyl sulfate-soluble α-synuclein were generally positively correlated with those of high molecular weight membrane-associated, sodium dodecyl sulfate-soluble α-synuclein and there was a trend for a positive correlation between striatal dopamine loss and 17-kDa membrane-associated, sodium dodecyl sulfate-soluble α-synuclein concentrations in multiple system atrophy. Brain membrane-associated, sodium dodecyl sulfate-soluble α-synuclein accumulations in Parkinson's disease and multiple system atrophy are regionally specific, suggesting that these sporadic α-synucleinopathies, unlike familial Parkinsonism-dementia, are not associated with a simple global over-expression of the protein. Despite a similar extent of dopamine depletion, the magnitude of brain membrane-associated, sodium dodecyl sulfate-soluble α-synuclein changes is disease specific, with multiple system atrophy clearly having the most severe accumulation. Literature discrepancies on α-synuclein status in 'Parkinson's disease' might be explained by inclusion of cases not having classic brainstem-predominant Lewy body disease and by variable α-synuclein accumulation within this diagnostic classification.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Canada</li><li>Japon</li><li>États-Unis</li></country><region><li>Vienne (Autriche)</li></region><settlement><li>Tokyo</li><li>Vienne (Autriche)</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Junchao Tong" sort="Junchao Tong" uniqKey="Junchao Tong" last="Junchao Tong">JUNCHAO TONG</name></noRegion><name sortKey="Ang, Lee C" sort="Ang, Lee C" uniqKey="Ang L" first="Lee C." last="Ang">Lee C. Ang</name><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name><name sortKey="Junchao Tong" sort="Junchao Tong" uniqKey="Junchao Tong" last="Junchao Tong">JUNCHAO TONG</name><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J." last="Kish">Stephen J. Kish</name><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name><name sortKey="Wong, Henry" sort="Wong, Henry" uniqKey="Wong H" first="Henry" last="Wong">Henry Wong</name></country><country name="États-Unis"><noRegion><name sortKey="Forno, Lysia S" sort="Forno, Lysia S" uniqKey="Forno L" first="Lysia S." last="Forno">Lysia S. Forno</name></noRegion><name sortKey="Muenter, Manfred D" sort="Muenter, Manfred D" uniqKey="Muenter M" first="Manfred D." last="Muenter">Manfred D. Muenter</name></country><country name="Japon"><noRegion><name sortKey="Shimadzu, Mitsunobu" sort="Shimadzu, Mitsunobu" uniqKey="Shimadzu M" first="Mitsunobu" last="Shimadzu">Mitsunobu Shimadzu</name></noRegion><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name><name sortKey="Furukawa, Yoshiaki" sort="Furukawa, Yoshiaki" uniqKey="Furukawa Y" first="Yoshiaki" last="Furukawa">Yoshiaki Furukawa</name></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:10-0060219
|texte= Brain α-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation
}}
| This area was generated with Dilib version V0.6.29. |  |